Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.
Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
Another trial of Medtronic's Symplicity renal denervation device in treating hypertension shows no benefit compared with a sham procedure.
New data from CardioMEMs CHAMPION clinical trial shows that the company's implanted pulmonary artery pressure monitor helps reduce heart failure hospitalizations without compromising kidney function in patients with renal failure.
St. Jude Medical (NYSE:STJ) subsidiary CardioMEMs touted new study results this week showing that its implanted heart monitor is safe and effective in patients with chronic kidney disease.
Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.
The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.
Medtronic's failed Symplicity HTN-3 renal denervation study doesn't look any better with 12 months of follow-up, according to new results presented at this year's European Society of Cardiology Congress.
Renal denervation technologies took another blow this week as 1-year results from Medtronic's (NYSE:MDT) much-lamented Symplicity HTN-3 trial still turned out no signs that the treatment is effective against hypertension.
The failure of Medtronic's Symplicity 3 trial doesn't mean the end of renal denervation in treated resistant hypertension, especially in Europe, but future studies face a high bar set by the Medtronic trial's sham control arm.
Kona Medical announces the launch of a clinical trial for its non-invasive Surround Sound renal denervation device for treating hypertension.
Kona Medical said this week that it's launched a clinical trial of the non-invasive renal denervation device for treating hypertension it calls Surround Sound.